US stock · Healthcare sector · Biotechnology
Company Logo

BridgeBio Pharma, Inc.

BBIONASDAQ

14.60

USD
+0.34
(+2.38%)
Market Closed
-5.16P/E
-6Forward P/E
-0.21P/E to S&P500
2.343BMarket CAP
- -Div Yield
Upcoming Earnings
2 Aug-7 Aug
Shares Short
5/15/23
13.29M
Short % of Float
14.26%
Short % of Shares Outs.
8.28%
% Held by Insiders
5.75%
% Held by Institutions
90.99%
Beta
0.70
PEG Ratio
0.08
52w. high/low
19.95/5.74
Avg. Daily Volume
3.13M
Return %
Stock
S&P 500
1 year
105.77
3.92
3 years
(50.69)
34.34
5 years
- -
55.95
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
48.36
17.61
71.56
14.23
73.50
11.20
18.13
4.98
19.95
7.10
Currency: USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.39
0.07
0.59
0.53
0.00
Earnings per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.33)
(2.12)
(2.48)
(3.80)
(4.77)
(3.26)
(1.64)
FCF per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.44)
(2.51)
(2.46)
(3.45)
(4.33)
(2.88)
(0.01)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
0.01
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.29
0.05
0.06
0.11
0.03
0.00
Book Value per sh.
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.63)
(2.66)
3.89
0.49
(7.38)
(8.51)
(0.03)
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
92
62
105
118
118
147
38,272
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(11.5)
(9.2)
(11.3)
(2.9)
(5.2)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.5)
(0.2)
(0.4)
(0.1)
(0.2)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.0%
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
41
8
70
78
78
Operating margin
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(656.4)%
(5,752.0)%
(827.1)%
(659.6)%
(12,902.0)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0
0
- -
3
6
7
26
Net profit (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(31)
(131)
(261)
(449)
(563)
(481)
(419)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
594.7%
Net profit margin
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(642.5)%
(5,439.7)%
(806.9)%
(619.7)%
(15,428.5)%
Working capital (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
89
413
508
547
710
417
456
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
55
92
476
1,726
12
12
Equity (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(58)
(164)
408
58
(870)
(1,255)
(1,214)
ROIC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(35.1)%
(34.6)%
(49.8)%
(73.6)%
(58.7)%
(65.5)%
328.5%
Return on capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(32.0)%
(31.8)%
(44.5)%
(62.9)%
(51.1)%
(64.3)%
(56.2)%
Return on equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
52.7%
79.7%
(63.8)%
(774.9)%
64.6%
38.4%
34.5%
Plowback ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
103.8%
100.0%
100.4%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
4 May · 2023 | Q1
All numbers in millions
Total liabilities
$ 1,839
Total assets
$ 626
Long-term debt
$ 12
Cash and equiv.
$ 407
Goodwill
$ - -
Retained earnings
$ (2,057)
Common stock
152,646
Enterprise Value
$ 1,948
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
607
788
82
Receivables
- -
20
- -
Inventory
- -
- -
- -
Other
36
70
29
Current assets
643
840
428
Acc. Payable
9
12
12
Debt due
5
5
4
Other
81
113
(4)
Current liabilities
96
130
12
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
11.38%
- -
- -
Cash flow
(16.99)%
33.26%
- -
Earnings
(14.46)%
45.60%
- -
Dividends
- -
- -
- -
Book value
44.14%
(498.48)%
- -
Insider Trading
Type
Shares
Date
Kumar Neil
Exempt
102,249
05/16/23
Kumar Neil
InKind
50,697
05/16/23
Kumar Neil
Sale
51,552
05/17/23
Kumar Neil
Exempt
5,129
05/16/23
Kumar Neil
Exempt
2,394
05/16/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
0
54
2
13
70
2022
2
74
0
2
78
2023
2
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
(1.38)
(0.82)
(1.32)
(1.42)
(4.94)
2022
(1.67)
0.40
(1.01)
(1.06)
(3.33)
2023
- -
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Dr. Neil Kumar Ph.D.
Full-time employees:
392
City:
Palo Alto
Address:
421 Kipling Street
IPO:
Jun 27, 2019
Website:
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Recent News